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1. Introduction 
Phencyclidine [ 1 -phenyl cyclohexylpiperidine] 
was introduced in the late 1950s as an intravenous 
general anesthetic that was non-toxic and non-in- 
flammable. The clinical advantages were unfortunately 
offset by its prolonged uration of action and psycho- 
tomimetic effects [I], properties that have contrib- 
uted to the emergence of phencyclidine as a major 
drug of abuse in the United States [2]. Phencyclidine 
produces long lasting psychosis thought o resemble 
schizophrenia more than any produced by other 
psychotomimetics [ 11. Phencyclidines have been 
expected for several years to interfere with the recog- 
nition of neurotransmitters at the level of their res- 
pective receptors [3,4]. They have been shown to 
interfere effectively with recognition processes at the 
level of the muscarinic and of the opiate receptors in 
the brain [5]. Since it is well known that the phar- 
macological properties of the acetylcholine receptor 
in the heart are those of a receptor of the muscarinic 
type [6], we have decided to analyse the structure- 
function relationships of a series of phencyclidines in
their action on cardiac ells in culture. Cultured 
cardiac ells have the advantage of being non- 
innervated. It is only with such a system that one can 
be sure that the observed effects of drugs are not of 
pre-synaptic nature. The results presented here show 
that molecules of the phencyclidine series when tested 
on the cardiac ell turn out to be agonists of the 
cholinergic muscarinic receptor with some interesting 
properties. 
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2. Materials and methods 
2 .I . Ventricle heart cells 
They were cultured from day 11 chick embryos 
according to [7]. Cells were used 4 days after plating. 
Under these conditions, cardiac ells form monolayers. 
They were also cultivated in the form of reaggregates. In 
this case, dissociated cells were plated into bacterial 
dishes (Falcon 1008 Petri dish). Spontaneous reaggre- 
gation occurs with the first 24-48 h culture. Reaggre- 
gates were used 3 days after plating. Beating rates and 
amplitude of reaggregated cells were recorded as in 
[8]. Until the reaggregates had reached astable beating 
frequency, they were continuously perfused by a 
standard medium (Hepes-Earle solution) at pH 7.4 
and 37°C. Then, phencyclidine, atropine and acetyl- 
choline were perfused to study their action on the 
beating properties. Studies with acetylcholine were 
done in presence of 10 I.~M eserine. 
2.2. Binding of / 3H]quinuclidinyl be&late (QNB) to 
heart cells in culture 
The properties of binding [3H]QNB, a muscarinic 
antagonist, were analysed as in [9,10]. Bindings were 
done directly in the Petri dish for monolayers and on 
homogenates for reaggregated cells [ 111. The com- 
peting molecule at the adequate concentration was 
incubated for 30 min in Earle-Hepes medium at 
pH 7.4,37%, with the cardiac ells prior to addition 
of 0.9 nM [3H]QNB for monolayers or 0.4 nM 
[3H]QNB for reaggregates. After another 35 min incu- 
bation, monolayers were washed 4 times at room 
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temperature with 1.5 ml incubation medium. The 
totat washing time was < 15 s. No dissociation occurs 
during washing near 22*C. Washed cells were then 
suspended in0.1 N NaOH and the bound radioactivity 
was measured using Picofluor. 13H]QNB binding on 
homogenates of reaggregated cardiac ells was accord- 
ing to [ 111. The specific binding of [‘H]QNB to 
cardiac ells in culture is the amount of binding 
which is prevented by concentration of non-tadioac- 
tive a&opine which saturates the muscarinic receptor 
(10 PM) or by saturating concentrations of the 
phencychdine derivatives. Under our experimental 
conditions, the amount of specific binding compared 
to total binding is 45-X% for monofayers and 95% 
for homogenates of rea~egates- All binding curves 
were fitted according to [ 12f. 
2 -3. Chemicals 
Molecules of the phencyclidine series were synthe- 
sized according to the methods in [ 131. Other 
chemicals were from standard sources. 
3. Results 
tive inotropic and negative chronotropic effect and 
stops the beating of cardiac ell reaggregates. Figure B 
shows the effect of phencyclidine (GKl) on the 
beating properties of the reaggregated cells. 
Phencyclidine gives the same negative inotropic and 
chronotropic effect as acetylcholine, GKl acts in a 
range of concentrations similar to the range of con- 
centrations necessary to see a~tyl~ho~ne action. 
However, in opposition with acetylchohne (fig.lA), 
reaggregates reated by phen~yc~d~e (fig.1 B) do not 
desensitize. Figure 1 C shows that the negative chrono- 
tropic and motropic effect of CR1 is completely 
prevented when the reaggregates are preincubated 
with atropine. A dose-response curve for GKl is 
shown in fig.2A and compared to the dose-response 
curve given with acetylcholine. GKl acts at 0.2-30 PM 
with a half-maximum effect at 0.4 PM. The dose- 
response curve for the protection of the effects of 
GR1 by atropine is given in fig.ZB. Atropine by itself 
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Fig.lA. Effect of acetylcholine on the rate and amplitude of 
beating of reaggregated cardiac cells of embryonic chick 
ventricles. (a) Control beating rate recorded from one reaggre- 
gate. (b) Addition of IO PM acetyl~ho~e decreases the rate 
aitd amplitude of beating; then after 1.20 min the beating is 
stopped, {ccf Desensitization occurs 3 mm later. 
Fig.1 B. Effect of GKl on the rate and amplitude of beating 
of reaggregate eel1 cultures. (a) Control beating rate recorded 
from one reaggregate. (b) Addition of 30 ,uM GKI decreases 
the rate and amplitude of beating; after 5.5 min, beatings are 
stopped as long as reaggregates are in the presence of GKJ 
(10 min). (c) On washing recovery occurs after 5 min. 
Fig.lC, Pratection of the effect of GKl on reaggregated ceB 
cultures. (a) Control beating rate recorded from one reaggre- 
gate bathed in Earle-Nepes solution containing 0.01 PM 
atropine. (b) 5 mm after addition of 30 PM GKl + 1 @i 
atropine. (c) 10 mm later. 
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Fig.2A. Beating-response curves for GKl (0) and acetylcholine 
(w), on reaggregated heart cells. Acetylcholine and phencych- 
dine trigger a negative inotropic and chronotropic effect and 
stop beating at 10 PM and 30 FM, respectively. The minimum 
beating rate at a given dose was plotted as percentage of the 
control rate. Fig.ZB. Dose-response curve of protection of 
the effects of GKI on reaggregated heart cells by different 
concentrations of atropine. GKl is used at a blocking con- 
centration (30 PM), atropine at 0.01-10 MM. Maximum 
effect of atropine is observed at 1 PM. The maximum beating 
rate at a given dose was plotted as percentage of the control 
rate before addition of GKl. The bars in fig.2 correspond to 
f SEM (n = 5-7). 
is without any effect on beating frequency. An 
important property differentiates GKl from acetyl- 
choline: with acetylcho~e, there is a very rapid 
de~n~tization of the ~hrono~opic and inotropic 
effect even in presence of eserine. The desensitization 
process does not exist with GKl. When the reaggre- 
gates are stopped, they do not recover their beating 
properties even after periods as long as 30 min GKl 
perfusion. However the reversibility of the effect of 
GKl is observed after S-10 min washing. 
3 -2. Interaction ofphencyclidines with the muscarinic 
receptor of embryonic cardiac cells in reaggregate 
and monolayer cultures 
As shown in fig.3, non-radioac~ve a~etylcho~ne, 
oxotremor~e and atropine in increasing concentra- 
tions compete with the muscarinic antagonist [3HJQNB 
for the association to the muscarinic receptor. Mole- 
cules of the phencyclidine series also compete with 
[‘H]QNB for the muscarinic receptor. ICse values for 
a series of molecules of the phencyclidine series are 
presented in table 1. IC,, values range from 
0.7-200 PM. It is interesting to remark that similar 
results are observed with cells in monolayers and in 
reaggregates (tig.3). It is well known that chick 
-9 [chelinergics er phencyciidinetl (Sn) 
Fig.3. Inhibition by molecules of the phencyclidine series 
and by cholinergic muscarinic antagonists and agonists of 
[ 3H]QNB binding to monolayers and reaggregated cultures of 
cardiac cells. Binding was carried out at 37°C with 0.9 nM 
[ 3H]QNB (monolayers, black symbols) or 0.4 nM (reaggre- 
gates, open symbols). (0, o) atropine, (A, a) GK4, (v, v) oxo- 
tremorine, (u, q ) GKl and (X) acetylcholine. Cells were 
incubated 20 mm with 10 .uM eserine before addition of 
acetylcholine. Inset A: Time course of specific association of 
0.9 nM 13H]QNB to cardiac cells in monolayer culture (pH 7.4, 
3FC). Inset B: Siding of ]jH]QNB to cardiac cells in mono- 
layer culture. Increasing amounts of [3H]QNB (44 Ci/mmol) 
were incubated at 37% (A) specific binding, (A) non-specific 
binding in the presence of 10 MM atropine. Ordinates: 
[ ‘H]QNB in fmol/mg protein. Maximum specific binding is 
500 fmol/mg protein and apparent equilibrium dissociation 
constant is KO.5 = 0.9 nM for monolayers. Maximum specific 
binding is 170 fmol/mg protein and K0.5 = 0.4 nM for 
reaggregates (results not shown). Each point in this figure 
represents the average of duplicate experiments. 
embryo cells cultivated in monolayers are insensitive 
to acetylcho~ne in their beating properties [141. 
Clearly these cells in monolayers have a muscarinic 
receptor with all the properties of a functional recep 
tor for binding of agonists and antagonists. However 
this receptor is most probably not coupled to the 
cation ionophores which regulate the chronotropic 
and inotropic properties of the normal cardiac ell. It 
is interesting to remark that if phencyclidine (or its 
analogues) isindeed a muscarinic agonist, one should 
observe binding of these molecules to the muscarinic 
receptor in cardiac ell monolayers but, similarly to 
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Table 1 
Inhibition by phencyciidines of ]sH]QNB bound, at equilibrium, to the muscarinic 
receptor of heart ceils in monolayer culture 
a Phenyl or Thienyl 4 1 
3 
Code Nomenclature of phencyclidine analogs 
GKO 
GK1 
GK2 
GK3 
GK4 
GKS 
GK6 
GK7 
GK8 
GK9 
GKl 1 
GK12 
GK14 
GK15 
l-(2-~ienyl)cyclohexylpiperi~e 31 
l-phenyl cyclohexylpiperidine (pheney~li~me) 55 
I-phenyl c-4-tert-butyl ~~yclohexylpiperi~me > 200 
I-phenyl t+tert-butyl ~~yclohexylpipe~d~e 6.9 
I-phenyl c-Q-methyl ~~yclohexylpiperid~e 0.7 
lphenyl t+methyl r-cyclohexylpiperidine 16 
1phenyl c-3-methyl r-cyclohexylpiperidine 25 
l-phenyl t-3-methyl r-cyclohexylpiperidine 15 
l-phenyl c-a-methyl r-cyclohexylpiperidine 19 
1-phenyl t-2-methyl rcyclohexylpiperidme 14 
1-(2-thienyl)c-2-methyl rcyclohexylpiperidine 40 
1-(2-thienyl)t-2-methyl r-cyclohexylpiperidine 78 
1-phenyl t-2.methoxy r-cyclohexylpiperidine 58 
1-phenyl c-2-methoxy r-cyclohexylpiperidine 8.1 
atropine 0.017 
bKd 
bM) 
“H 
16 1.0 
28 0.9 
3.5 1.0 
0.4 0.8 
8 0.9 
12.5 0.9 
I 0.8 
9 0.8 
7 0.9 
20 0.9 
39 0.8 
29 0.9 
4 0.8 
0.009 0.9 
a ZC,, is the concentration of unIabeled drug which induces ha~displa~ment of special- 
caJly bound [ %J]QNB, in the experimental conditions 
b Kd is the apparent equilibrium dissociation constant of the complex formed between 
cardiac cells in culture and the unlabeled drug. When the Hill coefficient (nH) is close to 
1.0, Kd is calculated from the IC,, value by the formula: 
ZC,, =Kd(l + [WQW~O.S(QNB)) 
where [sH]QNB is the concentration.of ree [‘H]QNB at half-inhibition and Ko.~(QNB) = 
0.9 nM calculated from direct saturation binding curve (see fig.3B) 
acetylchohne, no effect on the beating properties. 
Ex~~rnent~ evidence shows this expectation to be 
correct. 
A number of control experiments were carried out 
in order to be sure that: 
(i) No binding has occurred on the small fibroblast 
population which always exists in cultures of 
cardiac ells in monolayers; 
(ii) The measured t3H]QNB association to the cell 
corresponds to binding and not to uptake. 
Cultures of chick embryo fibroblast cells do not show 
any specific binding of fsH]QNB. Qn the other hand, 
monolayer cells treated for 1 h with 0.3 mM, 2,4- 
dinitrophenol to deplete the intracellular store of 
ATP from 8 mM down to 80 @VI 1151 display 
[%I]QNB binding properties identical to those of 
untreated cells. Since the met~bo~c ~bitor that 
blocks uptake systems i without effect on the binding 
of [3HJQNB and on the competition between 
phencyclidines and [%I]QNB, it seems reasonable to
assume that uptake of QNB is not occurring and that 
binding is the major feature. 
4. Discussion 
Phencyclidine provokes both a negative inotropic 
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and a negative chronotropic effect on chick embryo 
cardiac ells in culture. These effects are very similar 
to those induced by acetylcholine. Therefore the 
experimental observations suggest that phencyclidine 
is an agonist-like molecule of acetylcholine for the 
muscarinic receptor of the cardiac ell. This conclu- 
sion is confirmed by the fact that atropine at very 
low doses protects against the effect of the phency- 
&dine. 
The general properties of the interaction of 
phencyclidine with cardiac ell reaggregates are the 
following: 
(i) Negative chronotropic and inotropic effect with 
arrest of the beating; 
(ii) In contrast o the situation observed with acetyl- 
choline, no desensitization is observed for 
phencyclidine at low or at high concentrations; 
(in) The action of phencyclidine isreversible after 
washing; 
(iv) The phencyclidine molecule manifests its effect 
in a range of concentrations similar to acetyl- 
choline; 
(v) The beating properties of cardiac ells in mono- 
layers do not respond to phencyclidme, an 
expected result if phencyclidine acts as agonist 
of acetylcholine on the muscarinic receptor. 
Similarly to oxotremorine, acetylcholine and 
atropine, phencyclidines antagonize the specific 
[3H]QNB binding to the muscarinic receptor. The 
main properties of the association of phencyclidines 
with the acetylcholine muscarmic receptor are the 
following: 
(i) The dissociation constants (Kd) of the complexes 
formed between the 14 phencyclidines assayed 
and the muscarinic receptor ange from 0.4 w 
to>39/.lM. 
The binding of phencyclidines to the muscarinic 
receptor is characterized by a Hill coefficient near 1 
(0.8-l .O), the interaction is therefore of the Michaelian 
type. 
(ii) There are differences between isomeric pairs. 
There is a considerable difference in affinity 
between GK2 and GK3 which are cis and trans isomers 
in position 1 of the cyclohexyl ring; there are also 
differences between GK4 and GKS. GK4 has more 
affinity for the muscarinic receptor. However the 
substituted compounds at position 2 or 3 of the 
cyclohexyl ring of phencychdines do not differ greatly 
in their affmity for the muscarinic receptor. 
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